Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1 ‐mutated acute myeloid leukaemia

(2021) Sanam Loghavi et al.   BRITISH JOURNAL OF HAEMATOLOGY

2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (Part 2A – Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B – Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)

(2021) Susan Spitz et al.   Bioanalysis

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

(2021) Abhishek Maiti et al.   Blood Advances

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

(2021) Michael Heuser et al.   BLOOD

High‐sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events

(2020) Ulrike Sommer et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML

(2020) Harald Herrmann et al.   Blood Advances

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

(2020) Nicholas J. Short et al.   Blood Advances

Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation

(2019) Piyanuch Kongtim et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

(2019) Samer A. Srour et al.   AMERICAN JOURNAL OF HEMATOLOGY

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

(2019) Steven Piccoli et al.   Bioanalysis

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

(2018) Mithun Vinod Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia

(2018) Lauren Veltri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

(2017) P Boddu et al.   LEUKEMIA

Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia

(2016) Juan Ouyang et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

(2016) Farhad Ravandi et al.   CANCER

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

(2015) Juan Ouyang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

(2015) Sue Richards et al.   GENETICS IN MEDICINE

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

(2014) J M Jaso et al.   BONE MARROW TRANSPLANTATION

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

(2013) H.-H. Zhu et al.   BLOOD

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria

(2013) Brent Wood et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY